Bevonescein

DRUG4 trials

Sponsors

Alume Biosciences, Inc.

Conditions

Head and Neck NeoplasmsHead and Neck SurgeryImagingNerve InjuryParotid NeoplasmSurgeryThyroid Neoplasms

Phase 1

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

CompletedNCT04420689

Alume Biosciences, Inc.Head and Neck Neoplasms, Imaging, Nerve Injury +3

Start: 2020-06-18End: 2022-02-15Updated: 2025-05-08

Phase 2

Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery

CompletedNCT06227585

Alume Biosciences, Inc.Head and Neck Surgery

Start: 2023-11-29End: 2025-11-24Updated: 2026-02-25

A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

RecruitingNCT06662097

Alume Biosciences, Inc.Imaging, Nerve Injury, Surgery

Start: 2024-10-16End: 2025-09-30Target: 64Updated: 2024-10-28

Phase 3

Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery

CompletedNCT05377554

Alume Biosciences, Inc.Surgery

Start: 2022-04-29End: 2025-11-24Updated: 2026-04-13

Related Papers

Intraoperative nerve-specific fluorescence visualization in head and neck surgery: a Phase 1 trial.

2025-07-025 citations